Literature DB >> 12128285

Prolactin as an autocrine/paracrine growth factor in human cancer.

Nira Ben-Jonathan1, Karen Liby, Molly McFarland, Michael Zinger.   

Abstract

Prolactin (PRL) has a dual function -- as a circulating hormone and as a cytokine. This understanding is based on PRL production and distinct regulation in extrapituitary sites, its binding to membrane receptors of the cytokine receptor superfamily, and activation of signaling pathways that promote cell growth and survival. There is increasing evidence that PRL plays a role in several types of cancer in reproductive and non-reproductive tissues via local production or accumulation. The expression of both PRL and its receptor in human cancer cell lines of diverse origin lends further support to its action as an autocrine/paracrine growth factor. Establishment of PRL as an active participant in tumorigenesis should inspire the development of novel therapies aimed at reducing tumor growth by suppressing PRL production or by blocking its receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12128285     DOI: 10.1016/s1043-2760(02)00603-3

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  45 in total

Review 1.  Extrapituitary production of anterior pituitary hormones: an overview.

Authors:  S Harvey; C Arámburo; E J Sanders
Journal:  Endocrine       Date:  2011-11-15       Impact factor: 3.633

Review 2.  Extrapituitary growth hormone.

Authors:  S Harvey
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

3.  Biological significance of prolactin in gynecologic cancers.

Authors:  Vera V Levina; Brian Nolen; YunYun Su; Andrew K Godwin; David Fishman; Jinsong Liu; Gil Mor; Larry G Maxwell; Ronald B Herberman; Miroslaw J Szczepanski; Marta E Szajnik; Elieser Gorelik; Anna E Lokshin
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

4.  Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study.

Authors:  Anton Pottegård; Timothy L Lash; Deirdre Cronin-Fenton; Thomas P Ahern; Per Damkier
Journal:  Br J Clin Pharmacol       Date:  2018-07-08       Impact factor: 4.335

Review 5.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

6.  Structure and function of a new class of human prolactin antagonists.

Authors:  Laura DePalatis; Colleen M Almgren; Jypji Patmastan; Mark Troyer; Todd Woodrich; Charles L Brooks
Journal:  Protein Expr Purif       Date:  2009-02-21       Impact factor: 1.650

7.  Negative regulation of prolactin receptor stability and signaling mediated by SCF(beta-TrCP) E3 ubiquitin ligase.

Authors:  Ying Li; K G Kuresh Kumar; Weigang Tang; Vladimir S Spiegelman; Serge Y Fuchs
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

8.  Does prolactin induce apoptosis? Evidences in a prostate cancer in vitro model.

Authors:  D Giuffrida; A Perdichizzi; M C Giuffrida; S La Vignera; R D'Agata; E Vicari; A E Calogero
Journal:  J Endocrinol Invest       Date:  2009-12-04       Impact factor: 4.256

Review 9.  Neuroendocrine influences on cancer biology.

Authors:  Premal H Thaker; Anil K Sood
Journal:  Semin Cancer Biol       Date:  2007-12-08       Impact factor: 15.707

10.  Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase.

Authors:  Elizabeth W LaPensee; Sandy J Schwemberger; Christopher R LaPensee; El Mustapha Bahassi; Scott E Afton; Nira Ben-Jonathan
Journal:  Carcinogenesis       Date:  2009-05-14       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.